$LLY may soon receive approval for their obesity drug, which may prove to be a blockbuster drug. It appears that the stock is rising in anticipation of results from a second Phase 3 trial, expected this month. This could be big if LLY can break above its green line ATH peak at $375.25. I have a very small position and will add to it if we get a GLB (green line break-out). Thanks to my stock buddy, Judy, for telling me about LLY many months ago.
